Chimeric Antigen Receptor Targeting CLA and CD142 Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for pancreas cancer, face challenges in selectively targeting and eliminating cancer cells without harming non-malignant cells, as existing immunotherapies may not effectively identify and engage specific antigens on cancer cells.
Innovation Solution
Development of ligands comprising antigen binding domains specific for antigens like CLA, CD142, CD73, CD49c, CD66c, CD104, CD318, and TSPAN8, which are engineered into chimeric antigen receptors (CARs) or expressed on immune cells to specifically bind and kill cancer cells, utilizing CARs with antigen binding domains conjugated to transmembrane and intracellular signaling domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunotherapies are used to treat cancer, then cancer cells may be eliminated, but non-malignant cells may also be harmed due to lack of specificity
Solution Approach 1:
The invention segments the immunotherapy approach by identifying and targeting specific antigens (CLA, CD142, CD73, CD49c, CD66c, CD104, CD318, TSPAN8) that are uniquely expressed on cancer cells. This segmentation allows the CAR to distinguish between malignant and non-malignant cells, eliminating cancer cells while preserving healthy cells.
Solution Approach 2:
The chimeric antigen receptor acts as an intermediary that bridges the immune system and cancer cells. The CAR contains an antigen binding domain that specifically recognizes cancer cell antigens, serving as a mediator that directs immune cells to attack only cancerous targets while ignoring healthy cells.
2Reliability
If CARs are engineered to target specific antigens on cancer cells, then treatment efficacy is improved, but device complexity increases
Solution Approach 1:
The invention merges multiple functional domains into a single chimeric antigen receptor construct. The CAR combines an antigen binding domain (scFv) with transmembrane and intracellular signaling domains (CD28, CD137, OX40, ICOS, or CD27 costimulatory domain plus CD3ζ triggering domain), creating an integrated molecule that performs antigen recognition, cell membrane anchoring, and immune activation functions simultaneously.
Solution Approach 2:
The CAR construct is designed with universal multi-functionality, incorporating various interchangeable costimulatory domains (CD28, CD137, OX40, ICOS, CD27) that can be selected based on the specific cancer type or therapeutic goal. This universality allows the same basic CAR structure to be adapted for different cancer targets while maintaining enhanced efficacy.
Data Source
AI summary
The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.